Goire GG, Arias OY, Reyes SRE

Language: Spanish
References: 16
Page: 1-4
PDF size: 107.45 Kb.

ABSTRACT

The coronavirus pandemic is currently the most relevant situation in the world due to its high infectious power and high lethality in various risk groups, where all people affected by it have real possibilities of acute cardiac complications, but patients with underlying cardiovascular diseases are the highest risk according to the data collected so far and therefore the acting doctors in this situation have additional reasons to remain alert with a view to avoiding these deadly complications or giving them the best possible management. In this article we present relevant data related to the cardiac complications produced by this lethal virus, which will allow us a better understanding of its serious repercussion on the cardiovascular system.

REFERENCES

1. Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020.

2. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020.

3. Guo T, Fan Y, Chen M, Wu X, y cols. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 27 Mar 2020. doi: 10.1001/jamacardio.2020.1017. PMID: 32219356. Fuente

4. Shi S, Qin M, Shen B, Cai Y, Liu T, y cols. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 25 Mar 2020. doi: 10.1001/jamacardio.2020.0950.PMID: 32211816. Fuente

5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020

6. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries 2020;14:125-128

7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020

8. http://www.siacardio.com/consejos/consejo-de-cardiologia-tropical/editoriales-consejo-de-cardiologia-tropical/infeccion-aguda-e-infarto-del-miocardio/

9. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020

10. Timothy F. Simpson RJK, Eric C. Stecker. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. 2020. https:// www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. Published 3/29/2020.

11. Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Therapeutic advances in infectious disease. 2013;1(5):155-165.

12. Neira V, Enriquez A, Simpson C, Baranchuk A. Update on long QT syndrome. Journal of cardiovascular electrophysiology. 2019; 30 (12): 3068-3078.

13. Enrique Asensio RA, William Uribe, Eduardo B. Saad, Luis C. Sáenz. Recomendaciones para la medición del intervalo QT durante el uso de medicamentos para el tratamiento de infección por COVID-19. 2020. https://t.co/a1ph6jw0DW?amp=1&fireglass_rsn=true.Published 3/30/2020.

14. Giudicessi JR, Noseworthy PA, Ackerman MJ. The QT Interval. Circulation. 2019;139 (24):2711-2713.

15. Jeffrey S. ACC guidance on cardiac implications of coronavirus. Medscape Medical News. February 13, 2020. Available at: https:// www.medscape.com/ viewarticle / 925244. Accessed March 23, 2020.

16. American College of Cardiology. ACC clinical bulletin: COVID-19 clinical guidance for the cardiovascular care team. Reviewed March 6, 2020. Available at: https://www.acc.org/~/media/665AFA1E710B4B3293138D14BE8D1213.pdf. Accessed March 23, 2020.